Credit:
Westend61 via Getty Images An early draft of a scientific paper about potential human immunity to the Cas9 protein caused the stock prices of companies developing CRISPR-based therapies to plummet last week as investors questioned whether the controversial genome-editing technology would ever be safe for humans. Matthew Porteus, lead author of the paper and an associate professor...